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Poster Session II S325patient should discontinue the agent because of adverse effects and
developed treatment related mortality within 100 days after trans-
plantation. PK was completed in 7 patients, and median area-un-
der-curve (AUC) was 246ngh/ml. Although median AUC was
417ngh/ml for the patients who got whole-blood trough over
7ng/ml, median AUC was 177 ngh/ml for the patients trough less
than 6ng/ml.
Conclusions: Because the once-daily modified release formulation
of tacrolimus showed as effective as Prograf, Graceptor might
be able to keep administration for the patients due to reduce stress.
To get enough level of AUC, we should keep whole-blood trough
over 7ng/ml. These findings indicate that the use of Graceptor in-
stead of Prograf for GVHD prophylaxis is beneficial for patients
undergoing UD-HSCT.477
TELOMERASE ACTIVITY IN REGULATORY T CELLS IS INVERSELY ASSOCI-
ATED WITH SEVERITY OF CHRONIC GRAFT-VERSUS-HOST DISEASE
(CGVHD) AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
(HSCT)
Kawano, Y., Kim, H.T., Matsuoka, K.-I., Smith, R., Lazo-Kallanian, S.,
Daley, J., Ho, V.T., Cutler, C., Koreth, J., Alyea, E.P., Antin, J.H.,
Soiffer, R.J., Ritz, J. Dana-Farber Cancer Institute, Boston, MA
CD4+CD25+Foxp3+ regulatory T cells (Treg) play an important
role in the maintenance of peripheral tolerance and control of
chronic graft versus host disease (cGVHD). Previous studies have
shown that Treg undergo extensive homeostatic proliferation after
allogeneic HSCT. However, Treg are also susceptible to apoptosis,
and the inability to maintain survival of rapidly proliferating Treg
may contribute to the development of cGVHD. Telomeres play an
important role in cell senescence and we examined whether telome-
rase activity and telomere length were associated with Treg homeo-
stasis after allogeneic HSCT and cGVHD. We examined Treg and
conventional CD4 T cells (Tcon) in 52 patients with hematologic
malignancies who survived more than 2 years after HSCT. Tcon
and Treg were purified by flow cytometric cell sorting. Relative telo-
mere length was measured by real time PCR. Telomerase activity
was measured by PCR-ELISA. Telomere length was significantly
shorter in Treg compared to Tcon in all patients (0.10 vs 0.25;
p\0.0001), but Treg telomere length was not correlated with sever-
ity of cGVHD. Treg telomerase activity and Treg number were
inversely associated with severity of cGVHD (Treg telomerase activ-
ity/Treg cell number/ul, 37/33 in no cGVHD, 34/20 in mild
cGVHD, 7/19 in moderate cGVHD, 1.2/8 in severe cGVHD; p\
0.0001, p 5 0.01, respectively). Ki-67 expression, a measure of pro-
liferation, was higher in Treg compared with Tcon in all patients
(5.7% vs 0.9%; p\0.0001), and Ki-67 in Treg was inversely associ-
ated with severity of cGVHD (p 5 0.002). Bcl-2 expression, a mea-
sure of susceptibility to apoptosis, in Treg was also inversely
associated with severity of cGVHD (p 5 0.0009). Finally, there
was a significant correlation between Treg telomerase activity and
Bcl-2 expression (r5 0.69, p\0.0001), suggesting that high telome-
rase activity is associated with other mechanisms that promote
survival of Treg. These data indicate that activation of telomerase
in Treg after allogeneic HSCT does not prevent overall telomere
shortening. However, telomerase activation increases the replicative
life span of Treg by protecting them from apoptosis. Failure to acti-
vate telomerase in Treg restricts their proliferative capacity and also
appears to increase apoptotic susceptibility, resulting in the loss of
peripheral tolerance and the development of severe cGVHD.478
HIGH IL-15 SERUM LEVELS ON DAY 7 AFTER HEMATOPOIETIC CELL
TRANSPLANTATION ARE ASSOCIATED WITH A LOW LIKELIHOOD OF
GVHD AND A HIGH LIKELIHOOD OF INFECTIONS
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Background:Hematopoietic cell transplantation (HCT) is typically
curative for hematologic malignancies. Unfortunately, success of
HCT is limited by side effects, primarily graft-vs-host disease(GVHD) and infections. As preemptive therapy of GVHD or infec-
tions would likely be efficacious if started early posttransplant, we set
out to determine whether the levels of IL-15 on day 7 are associated
with subsequent development of GVHD or infections.
Patients and Methods: In 158 allogeneic transplant recipients we
determined serum IL-15 levels using sandwich ELISA (R&D). IL-
15 levels in patients with versus without aGVHD (grade 2-4),
cGVHD (needing systemic therapy) or relapse were compared using
Mann-Whitney-Wilcoxon test, and correlation with infection rates
were evaluated using Spearman rank correlation test. Multivariate
analyses were performed adjusting for recipient age, donor type,
donor/recipient sex, stem cell source and, for relapse, also disease/
disease stage and, for infections, also engraftment day and aGVHD
or cGVHD.
Results: In univariate analyses IL-15 levels were significantly associ-
ated with aGvHD and cGvHD (median 29 vs 40 pg/mL in patients
with vs without aGVHD, p5 .02, and median 25 vs 40 pg/mL in pa-
tients with vs without cGVHD, p5 .02). IL-15 levels were similar in
patients who did vs did not develop relapse (30 vs 39 pg/mL, p 5
0.60). There was a positive correlation between IL-15 levels and
the rates of definite (microbiologically documented) infections
(p5 .008), total (definite or presumed) infections (p5 .008), viral in-
fections (p5 .06), bacterial infections (p5 .06) and fungal infections
(p5 0.03) occurring between day 7 and 83. In multivariate analyses,
IL-15 levels above 31.0 pg/mL were associated with a 0.38-fold risk
of aGVHD (p 5 0.005), and levels above 31.3 pg/mL with a 0.35-
fold risk of cGVHD (p\ .008). For a unit increase of IL-15 level
(change of 1 pg/mL), the rate of infections increased 1.02-fold
(p\ .001) for definite infections, 1.03-fold for total infections (p\
.001), 1.03-fold for viral infections (p\ .001), 1.02-fold for bacterial
infections (p\ .001) and 1.03-fold for fungal infections (p 5 .06).
Conclusion:High IL-15 levels were associated with a low likelihood
of GVHD and a high likelihood of infections, including viral, bacte-
rial and fungal infections. Thismay reflect the fact that themost lym-
phopenic patients may have had the highest levels of IL-15,
a homeostatic growth factor for CD8 T cells and NK cells.479
PREDICTIVE VALUE OF SCORING SYSTEM WITH AUTOANTIBODY
EXPRESSIONS IN ALLOGENEIC STEM CELL RECIPIENTS
Sohn, S.K.1, Moon, J.H.1, Do, Y.R.2, Lee, S.J.1, Kang, B.W.1,
Chae, Y.S.1, Kim, J.G.1 1Kyungpook National University Hospital,
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Background: In our previous study, patients expressing autoanti-
bodies especially ANA showed a better survival in allogeneic stem
cell recipients. The current study was designed to implicate the ex-
pression of autoantibodies as an prognostic marker after allogeneic
stem cell transplantation (SCT).
Methods:A total of 144 consecutive patients who underwent alloge-
neic SCT from November 2001 to Sep 2009 and survived at least 3
months were included in the current study. ANA and anti-dsDNA
were screened at 3, 6, 12 month and yearly thereafter.
Results:ANAwas positive in 31 patients (21.5%) at median 364 days
(range, 90-1141) and anti-dsDNA (. 3.0 IU/mL) in 76 (52.8%) at
median 100 days (range, 46-1458). In the multivariate analysis,
ANA [hazard ratio (HR) 0.315] and anti-dsDNA . 3.0 IU/mL
(HR 0.328) were identified as good prognostic factors for survival
and relapse. When scored as the number of autoantibody expression
with ANA and anti-dsDNA; score 0 as no autoantibody expression,
score 1 as one and score 2 as two, the patients for score 2 showed
a 91.8% 5-yr overall survival (OS) (HR 0.075, p \ 0.001) and
0.4% relapse rate (HR 0.059, p \ 0.006), those for score 1
a 64.1% 5-yr OS (HR 0.352, p \ 0.001) and 26.3% relapse rate
(HR 0.422, p 5 0.011), and those for score 0 a 35.7% 5-yr OS and
53.7% relapse rate.
Conclusion: Patients expressing multiple autoantibodies (ANA and
anti-dsDNA) showed a better survival and lower relapse rate in allo-
geneic stem cell transplantation settings. Scoring with autoantibody
expressions could be used as a prognostic marker for long-term
survival and lower relapse risk after allogeneic SCT.
